Trial reportNeuroImage. Clinical2014
Neuroprotective effects of testosterone treatment in men with multiple sclerosis.
Trial report in NeuroImage. Clinical, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial
A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis
Who cites it
63 citing papers in PubMed, 128 citations in OpenAlex.
- Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.JAMA neurology · 2016Trial
- Understanding the Role of Hypothalamic-Pituitary-Gonadal Axis in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.Biomedicines · 2026Review
- Highlight on Dr. Rhonda Voskuhl: a pioneer in the exploration of sex differences in the immune response.Biology of sex differences · 2026Article
- Article
- The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.Neuroscience and biobehavioral reviews · 2025Review
- Sex-Related Differences in Lifestyle Factors Affecting Multiple Sclerosis Susceptibility and Disease Progression.Brain sciences · 2025Review
- Neurology of Androgens and Androgenic Supplements.Current neurology and neuroscience reports · 2025Review
- Exploring the role of sex hormones and gender diversity in multiple sclerosis.Nature reviews. Neurology · 2025Article
- Association between levels of sex hormones and risk of multiple sclerosis: a mendelian randomization study.Acta neurologica Belgica · 2024Article
- Neurologic Care for Transgender and Gender-Diverse People: A Review of Current Evidence and Clinical Implications.Neurology. Clinical practice · 2024Review
- Sex-related variability of white matter tracts in the whole HCP cohort.Brain structure & function · 2024Article
- Sex- and species-specific contribution of CD99 to T cell costimulation during multiple sclerosis.Biology of sex differences · 2024Article
- The Impact of Microbiota-Immunity-Hormone Interactions on Autoimmune Diseases and Infection.Biomedicines · 2024Review
- Interplay between androgen and CXCR4 chemokine signaling in myelin repair.Acta neuropathologica communications · 2024Article
- Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data.Current neurology and neuroscience reports · 2024Review
- Sex hormone therapy in Multiple Sclerosis: A systematic review of randomized clinical trials.Journal of central nervous system disease · 2024Review
- Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25-year projection: An analysis of the Global Burden of Diseases Study.Health science reports · 2023Article
- Pregnenolone 16α-carbonitrile negatively regulates hippocampal cytochrome P450 enzymes and ameliorates phenytoin-induced hippocampal neurotoxicity.Journal of pharmaceutical analysis · 2023Article
- Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.Laboratory investigation; a journal of technical methods and pathology · 2023Article
- Androgens show sex-dependent differences in myelination in immune and non-immune murine models of CNS demyelination.Nature communications · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system. While current medication reduces relapses and inflammatory activity, it has only a modest effect on long-term disability and gray matter atrophy. Here, we have characterized the potential neuroprotective effects of testosterone on cerebral gray matter in a pilot clinical trial. Ten men with relapsing-remitting MS were included in this open-label phase II trial. Subjects were observed without treatment for 6 months, followed by testosterone treatment for another 12 months. Focal gray matter loss as a marker for neurodegeneration was assessed using voxel-based morphometry. During the non-treatment phase, significant voxel-wise gray matter decreases were widespread (p≤ 0.05 corrected). However, during testosterone treatment, gray matter loss was no longer evident. In fact, a significant gray matter increase in the right frontal cortex was observed (p≤ 0.05 corrected). These observations support the potential of testosterone treatment to stall (and perhaps even reverse) neurodegeneration associated with MS. Furthermore, they warrant the investigation of testosterone's neuroprotective effects in larger, placebo controlled MS trials as well as in other neurodegenerative diseases. This is the first report of gray matter increase as the result of treatment in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.